Beyond Efficacy: Cost and Resource Implications of First-Line Systemic Therapies for Metastatic Renal Cell Carcinoma Talquetamab is a G protein–coupled receptor class C group 5 member D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback